• 沒有找到結果。

Case reports of BRONJ Case reports of BRONJ

N/A
N/A
Protected

Academic year: 2022

Share "Case reports of BRONJ Case reports of BRONJ"

Copied!
61
0
0

加載中.... (立即查看全文)

全文

(1)

Case reports of BRONJ Case reports of BRONJ

指導老師 : 王文岑醫師暨口腔病理科全體醫師

實習 E 組 Intern 廖昱豪 張庭維

謝旻芸 黃于芳 曾家展

(2)

General data

• Name : 葉 x 英

• Gender: Female

• Age : 76 y/o

• Native : 屏東縣

• Marriage status : Married

• Occupation : 無

Case 1

(3)

Chief Complaints

R’t submandibular swelling for 2 months

(4)

Present Illness

• 97.12.11

– This 74 y/o female was suffered from the

above episode, at first she went to LDC , the dentist suggest ed her to come to our OPD for further examination. She took Fosamax.

– 2 polyps at right edentulous ridge, local pus (+)

– Right submandibular swelling about 5*7cm

(5)

Past History

Past Medical History

• Hypertension(+) DM(-) denied other systemic illness

• Hospitalized: 置換人工膝關節

• osteoporosis

• drug or food allergy: penicillin

• Medication:

drug for hypertension control 膝關節藥物

Forsamax (alendronate( 口服 ) 次 / 週 for 4~5 yrs )

(6)

• Past Dental History

Extraction ,C&B,OD,RCT

• Attitude to Dental Tx : Fair

• Oral Habits

Alcohol : (-)

Betel quid : (-)

Cigarette (-)

(7)

• 3x3 cm

• Mixed RL with RO, irregular shape bony

destruction

(8)
(9)

Differential Diagnosis

●Tumor

• Benign (X)

• Malignancy

osteosacoma

odontogenic malignancy tumor

●Infection

Osteomylities

(10)

Clinical impression

• Bisphosphonate- related osteonecrosis of

jaw (BRONJ)

(11)

Treatment course

97.12.11 (first visit) refer from LDC 97.12.11 (first visit) refer from LDC I&D

anaerobic culture, aerobic culture Rx: amoxicillin/ panadol / suwell

97.12.18 97.12.18

pus culture report

Clostridium bifermentans

→metronidazole(+) Ampicillin (+)

Clindamycin (+)

(12)

97.12.12~97.12.31 97.12.12~97.12.31 N/S irrigation

Antibiotic

98.1.7 98.1.7

arrange OP

98.1.15 98.1.15

OP: sequestrectomy +saucerization

(13)

• 98.3.4

(14)

• 98.5.6

Remove sequestrum (in OPD)

(15)

• 98.9.16 F/U

(16)

General data

• Name : 涂沈秀月

• Gender: Female

• Age : 51 y/o

• Native : Kaohsiung

• Marriage status : Married

• First Visit : 97/12/18

Case 2

(17)

Chief Complaints

• Ask for oral examination for dental care after 骨針 application

• Bad smell from wound of extraction for

more than 1 year.

(18)

Present Illness

• 97/12/18

This 49 y/o female has received Zometa IV monthly for bone metastasis for about 3 years. And the nurse of cancer center

suggested her to visit our OPD for oral examination.

She stated she had extraction

experience of teeth 15 and 16 more than

1 year ago in LDC.

(19)

Past History

Past Medical History

• Breast carcinoma with bone metastasis (T1N2M1)s/p operation , systemical

chemotherapy and radiotherapy.

• Serous microcystic adenoma over pancreatic tail s/p partial pancreatectomy

• Otitis media s/p eardrum reconstraction

• Tonsil excision

(20)

Past Dental History

• Extraction, C&B fabrication, OD, scaling

Attitude to Dental TxFair

Oral Habits Related to Malignancy:

• Alcohol : (-)

• Betel quid : (-)

• Cigarette : (-)

(21)

Oral Examination

• A fistula was found on edentulous ridge of teeth 15 &16, tracing with GP to take a periapical film.

• Missing:

– 15,16,17,18,27,28,37,38,45,46,48

• Caries : 13(D),14(M),34(B)

• Metal crown : 22,23,24,25,26,35,36,44xx47

• PFM crown: 42

(22)

Panorex findings

There is an ill-defined bony destruction area

about 2x2cm in diameter over edentulous ridge of teeth 15 and 16 .

(23)

Differential diagnosis

• Bisphosphonate related osteomyelitis over R’t post. Maxilla

• Breast carcinoma with bone metastasis of jaw

• Osteoradionecrosis of the jaw (ORN)

Clinical Impression :

Bisphosphonate-Related Osteonecrosis of the

Jaw (BRONJ)

(24)

Treatment Plan

• Antibiotic therapy

• Local debridement

• Advanced surgical management

(25)

98.8.13

(26)

Cases review of BRONJ

(KMUH)

(27)

Cases review

•Patient source:

14 BRONJ patients in KMUH dental dept.

•Methods: chart review

1.bisphosponate(BP) usage 2.radiographic evaluation

3.systemic condition

4.oral hygiene and dental condition

(28)

General data

Sex:

Male : Female = 0:14 (female 100%) Age:

21-50 y/o: 1 (7.1%) 51-60 y/o: 2 (14.2%) 61-70 y/o: 3 (21.3%) 71-80 y/o: 6 (42.6%) 81-90 y/o: 2 (14.2%)

Range: 42-82, average : 69 y/o Reason for BP usage:

Breast ca (BC) with bone meta or prevention: 6(42.8%), Osteoporosis: 8(57.2%)

DM: 5 (35.5 %)

(29)

• BC

Z P+Z B+Z

Oral

IV 3 2

Oral+IV 1

• O

A :8 (oral)

P: pamidronate

Used form of BP

(30)

Using time of BP(months)

• 11-30m: 3

• 31-50m: 6

• 51-70m: 1

• 71-90m: 2

• 101-110m: 1

• Minimum: 13m (A/oral)

• Maximum:103m (A/oral)

• Average: 47m

• Side effect:

not obvious

(31)

0 1 2 3

1(7.1%) 8(57.1%) 4(28.6%) 1(7.1%)

• Bony exposure:12/14(85.7%)

• Lesion Numbers

Location Upper Ant.

Upper premolar

Upper molar

Lower anterior

Lower premolar

Lower molar No.(%) 1 (5.6%) 2 (11.1%) 2(11.1%) 2(11.1%) 4(22.2%) 7(38.9%)

Locations

Locations

Lesion characteristics

(32)

•Symptoms and signs

Pain 14/14 100% 1

Swelling 9/14 64.3%

Delayed healing wound (sockets) 11/14 78.6% 3 neurosensory changes 3/14 21.4%

Pus 13/14 92.9% 2

Intraoral sinus tract extraoral fistula

8/14 57.1%

Tooth mobility 5/14 35.7%

X ray finding 14/14 100% 1

Clinical characteristics

(33)

Clinical characteristics

• Radiographic features

Radiolucency RO mixed

10 (71.4%) 0 4 (28.6 %)

• Lesion size

Maxium: 5*3 cm Minimum: 1*1 cm

(34)

•ONJ staging

0 1 2 3

0 1/14

(7.1%) 12/14

(85.7%)

2/14

(14.3%)

• Special events

none

extraction

Other

2/14

(14.3%)

11/14 (78.6%) 1/14

(tooth Fx) (7.1%)

(35)

• 使用 bisphosphonate 到發病時間

< 1m 1m 2~3m 12m

2 4 1 1

11~30m 31~50m 51~70m 71~90m 91~110m

4 4 2 1 1

Event~ BRONJ Event~ BRONJ

Minima: 12 Maxima: 94 Average: 44.8 Minima: 12 Maxima: 94 Average: 44.8

(36)

Clincal procedures & treatments

• Biopsy: 7/14 (50%)

• Bacterial culture: 6/14 (42.9%) Clostridium bifermentans

staphylococus epidermidis propionibacterium species

• Antibiotic: 14/14 (100%)

amoxicillin, clindamycin, metronidazole, clindamycin,

• Local irrigation and debridement: 12/14 (85.7%)

• Operation (in OR) : 6/14 (42.9%)

• HBO : 4/14 (28.6%)

(37)

• Periodontitis: 12/14 (85.7%)

• 感染性骨髓炎 :

Upper anterior

Upper premolar

Upper molar

Lower anterior

Lower premolar

Lower molar

3 site 0 site 0 site 3 site 7 site 8 site

(38)

conclusion

• 更年期過後的婦女因為罹患乳癌和骨質疏鬆症的 機率增加,用藥機率增加,所以為高危險群

• 藥物本身副作用不明顯,所以使用普遍

• 11/14 (78.6%) 的病人是因為拔牙傷口不癒合,且 大多數病灶部位都在下顎後牙區

• 病患大多在服藥後 1~5 年內發病,平均 44.8m

• 所有來診的患者皆有疼痛 (100%) 的情況,其次

為化膿 (92.9%) ,可見一般民眾會因為疼痛尋求

解決,或是化膿意識到嚴重性求診

(39)

Discussion

Discussion

(40)

INDICATIONS AND BENEFITS OF INDICATIONS AND BENEFITS OF

BISPHOSPHONATE BISPHOSPHONATE

• Bps. have high affinity for hydroxyapatite , remaining unmetabolized for long periods of time.

• During bone remodeling, the drug is taken up by osteoblast and internalized in the cell cytoplasm.

• Reducing recruitment and proliferation of osteoclast precursors and inducing osteoclast apoptosis.

• Bps. also have antiangiogenic properties and may be directly tumoricidal.

As a result, bone turnover becomes As a result, bone turnover becomes

profoundly suppressed, and over time the profoundly suppressed, and over time the

bone shows little physiologic remodeling bone shows little physiologic remodeling.

As a result, bone turnover becomes As a result, bone turnover becomes

profoundly suppressed, and over time the profoundly suppressed, and over time the

bone shows little physiologic remodeling

bone shows little physiologic remodeling.

(41)

INDICATIONS AND BENEFITS OF INDICATIONS AND BENEFITS OF

BISPHOSPHONATE THERAPY BISPHOSPHONATE THERAPY

• IV Bisphosphonates

cancer-related conditions

1.hypercalcemia of malignancy

2.bone metastases (breast cancer, prostate cancer , lung cancer)

3.lytic lesions of multiple myeloma

• Pamidronate(Aredia), Zoledronic acid(Zometa), Zoledronate(Reclast), Ibandronate(Boniva)

J Oral Maxillofac Surg 67:2-12, 2009, Suppl

(42)

• Oral Bisphosphonates

1. most prevalent and common indication  osteoporosis 2. Paget’s disease of bone and osteogenesis imperfecta of

childhood.

• Off-label uses

 Numerous other conditions where a decrease in bone remodeling by bisphosphonates might aid in disease management:

– giant cell lesions of the jaw

– pediatric osteogenesis imperfecta – fibrous dysplasia

– Gaucher’s disease

J Oral Maxillofac Surg 67:2-12, 2009, Suppl

(43)

Common bisphosphonates

Common bisphosphonates

(44)

Relative Potency Relative Potency

• Etidronate (Didronel) Etidronate (Didronel) 1 1

• Tiludronate (Skelide) Tiludronate (Skelide) 10 10

• Pamidronate (Aredia) Pamidronate (Aredia) 100 100

• Alendronate (Fosamax) Alendronate (Fosamax) 1,000 1,000

• Risedronate (Actonel) Risedronate (Actonel) 10,000 10,000

• Ibandronate (Boniva) Ibandronate (Boniva) 10,000 10,000

• Zolendronic acid (Zometa) Zolendronic acid (Zometa) >100,000 >100,000

*

Relative to etidronate (a non-nitrogen-containing

bisphosphonate with relative potency of 1).

(45)

BRONJ Case Definition BRONJ Case Definition

Patients may be considered to have BRONJ

1. Current or previous treatment with a bisphosphonate.

2. Exposed bone in the maxillofacial region that has persisted for

more than 8 weeks.

3. No history of radiation therapy to the jaws

J Oral Maxillofac Surg 67:2-12, 2009, Suppl

(46)

Incidence of BRONJ Incidence of BRONJ

• IV BISPHOSPHONATES

0.8% to 12%

• ORAL BISPHOSPHONATES

 0.7/100,000 person-years of

exposure(Merck)underreporting.

 Surveillance data from Australia (patients treated weekly with alendronate )  0.01% to 0.04%

 13,000 Kaiser-Permanente members( long-term oral bps)

0.06%

 IV>>oral.

Independent epidemiological efforts from clinicians and the International Myeloma Foundation reported

incidence estimates between 5% ~ 10%.

J Oral Maxillofac Surg 67:2-12, 2009, Suppl

(47)

RISK FACTORS RISK FACTORS

1. Drug-related risk factors

A. Bisphosphonate potency

zoledronate (Zometa)> pamidronate(Aredia)> oral bps.

B. Duration of therapy

2. Local risk factors

A. Dentoalveolar surgery: 5-~21-fold increased risk in IV Bps. treated cancer patients.

B. Local anatomy : Mandible : Maxilla=2:1

(Thin mucosa overlying bony prominences such as tori , bony exostoses, and the mylohyoid ridge)

C. Concomitant oral disease: history of inflammatory dental disease are at a 7-fold increased risk.

J Oral Maxillofac Surg 67:2-12, 2009, Suppl

(48)

3. Demographic and systemic factors A. increasing age ; whites.

B. systemic factor (renal dialysis, low hemoglobin, obesity, and diabetes)

C. chemotherapeutic agents (cyclophosphamide, erythropoietin, and steroids)

D. tobacco users, alcohol exposure(X) …Wessel et al

4. Genetic factors

single nucleotide polymorphisms, in the cytochrome P450-2C gene [CYP2C8] ……… Sarasquete et al

J Oral Maxillofac Surg 67:2-12, 2009, Suppl

(49)

Staging of BRONJ Staging of BRONJ

• Patient at risk :

no apparent necrotic bone in asymptomatic patients who have been treated with IV or oral Bps.

• Stage 0 : no clinical evidence of necrotic bone, present with nonspecific symptoms or findings, include

Symptoms:

1. Odontalgia not by an odontogenic cause

2. Dull, aching bone pain in the body of the mandible 3. Sinus pain

4. Altered neurosensory function

Clinical findings:

1. Loosening of teeth not explained

2. Fistula not associated with pulpal necrosis Radiographic findings:

1. Persistence of unremodeled bone in sockets 2. Thickening/obscuring of periodontal ligament

3. Inferior alveolar canal narrowing

(50)

• Stage1 :

exposed and necrotic bone in patients who are asymptomatic and have no evidence of infection.

(51)

• Stage2 : exposed and necrotic bone in patients

with pain and clinical evidence of infection(pain,

erythema , purulent drainage.)

(52)

• Stage3: exposed and necrotic bone in patients with

pain, infection, and one or more of the following:

1. Exposed necrotic bone extending beyond the region of alveolar bone

2. Pathologic fracture 3. Extraoral fistula

4. Oral antral/oral nasal communication

5. Osteolysis extending to the inferior border of the

mandible or sinus floor

(53)

Treatment stretagy Treatment stretagy

At risk:

Not require any treatment.

Patient education.

Stage 0:

Systemic management, including use of pain medication and antibiotics

Stage 1:

Antibacterial mouth rinse(0.12% CHX) Clinical follow-up

No surgical treatment is indicated

.

(54)

Stage2:

• Symptomatic treatment with oral antibiotics (adjusted according to culture )

• Oral antibacterial mouth rinse

• Pain control

• Superficial debridement to relieve soft tissue

irritation.

Stage3:

• Antibacterial mouth rinse

• Antibiotic therapy and pain control

• Surgical debridement / resection for longer term

palliation of infection and pain.

(55)

Treatment strategy and advisements Treatment strategy and advisements

Patients About to Initiate IV:

• If systemic conditions permit, initiation of Bps. therapy should be delayed until the dental health has been

optimized.

• if systemic conditions permit, until the extraction site has mucosalized (14 to 21days) or until adequate osseous healing has occurred.

• Patients be educated as to the importance of dental hygiene and regular dental evaluations and specifically instructed to report any pain, swelling , or exposed.

(56)

Asymptomatic Patients Receiving IV Bisphosphonates:

• Avoid direct osseous injury .

• The efficacy of a drug holiday for patients receiving yearly zoledronic acid therapy and the appropriate timing of

dentoalveolar surgery is unknown.

Asymptomatic Patients Receiving Oral Bisphosphonate :

• A. Patients are adequately informed of the small risk of compromised bone healing.

• B. The use of bone turnover marker levels, in conjunction with a drug holiday, has been reported as an additional tool to guide treatment decision.

(57)

C. For individuals taken an oral bps. for fewer than 3 years and have no clinical risk factors.

no alteration or delay in the planned surgery is necessary.

D. For fewer than 3 years and have also taken corticosteroids concomitantly

consider discontinuation of the oral bps. for at least 3 months before & after oral surgery.

(58)

Patients with BRONJ

• Treatment objectives eliminate pain, control infection of the soft and hard tissue, and minimize the progression or occurrence of bone necrosis.

• Surgical debridement is variably effective

Difficult to obtain a surgical margin in early stage.

 Surgical treatment should be delayed if possible.

• Stage 3 disease might require resection and immediate reconstruction with a reconstruction plate or an obturator .

(59)

• Hyperbaric oxygen therapy has some

improvement in wound healing and long-term pain scores, but its use as the sole treatment

modality for BRONJ cannot be supported at this time.

• Other non-invasive treatment:

platelet-rich plasma, parathyroid hormone, and bone morphogenic protein..-->need more study

.

J Oral Maxillofac Surg 67:96-106, 2009, Suppl 1

J Oral Maxillofac Surg 2007; 65: 573- 80.

(60)

• Mobile segments of bony sequestrum should be removed .

• Extraction of symptomatic teeth within exposed,

necrotic bone should be considered because it is unlikely that extraction will exacerbate established necrotic

process.

• Long-term discontinuation of IV Bps might be beneficial.

(1~2 years)

• Discontinuation of oral Bps for 6-12 months may result in either spontaneous sequestration or resolution after

debridement surgery.

(61)

Thank you for your attention!!

Thank you for your attention!!

參考文獻

相關文件

19 Genetic testing for the HFE mutation is indicated in all first-degree relatives of patients with hemochromatosis and also in patients with evidence of iron overload 20

 Stage 3 Exposed ⁄ necrotic bone in patients with pain, infection, and one or more of the following: exposed and necrotic bone extending beyond the region of alveolar bone

The clinical and radiological features of 6 cases of NBCCS were characterized into major and minor criteria and compared with features reported in Indian patients and in patients

This retrospective magnetic resonance imaging study of patients under 21 years of age found that these young patients are susceptible to all stages of disk displacement and that

Loss of vascular content, increase of fat in the bone marrow cavity, and fibrosis showed a linear relation with time after radiation and were considered the end stage of

pylori in pathogenesis of oral mucosal lesions or ulcerations is still unclear, it seems that patients with oral lesions as leukoplakia and oral lichen planus, and concurrent

A sixty-year-old female patient came to the Department of Oral and Maxillofacial Surgery, Faculty of Dental Medicine, Cairo University, complaining of bilateral swellings in

Up-and-coming mandibular reconstruction technique with autologous human bone marrow stem cells and iliac bone graft in patients with large